Glioblastoma is the most common malignant primary intracranial tumor and, despite multi-modal treatment, the prognosis remains poor. Additional tools to improve early detection or evaluate treatment response are highly desirable. We evaluated serial ADC measurements in the T2-hyperintense, but otherwise normal-appearing white matter at 1.5 T in thirty-five subjects diagnosed with glioblastoma and treated by surgical resection, radiotherapy, temozolomide and tumor-treating fields. We found that serially increasing ADC in the T2-hyperintense, but otherwise normal-appearing white matter in glioblastoma patients is prognostically favorable, with significantly greater overall survival and progression-free survival in patients with increasing ADC.
This abstract and the presentation materials are available to members only; a login is required.